| Knowledge4COVID-19

Property	Value
is ?:annotates of	<https://research.tib.eu/covid-19/entity/32439716_HAS_TOPIC_C0006142> <https://research.tib.eu/covid-19/entity/32439716_HAS_TOPIC_C0014410> <https://research.tib.eu/covid-19/entity/32439716_HAS_TOPIC_C0018736> <https://research.tib.eu/covid-19/entity/32439716_HAS_TOPIC_C0032310> <https://research.tib.eu/covid-19/entity/32439716_HAS_TOPIC_C0034019> <https://research.tib.eu/covid-19/entity/32439716_HAS_TOPIC_C0086287> <https://research.tib.eu/covid-19/entity/32439716_HAS_TOPIC_C0086418> <https://research.tib.eu/covid-19/entity/32439716_HAS_TOPIC_C0162648> <https://research.tib.eu/covid-19/entity/32439716_HAS_TOPIC_C0206750> <https://research.tib.eu/covid-19/entity/32439716_HAS_TOPIC_C0243004> <https://research.tib.eu/covid-19/entity/32439716_HAS_TOPIC_C0243005> <https://research.tib.eu/covid-19/entity/32439716_HAS_TOPIC_C0678222> <https://research.tib.eu/covid-19/entity/32439716_HAS_TOPIC_C1257931> <https://research.tib.eu/covid-19/entity/32439716_HAS_TOPIC_C1328956> <https://research.tib.eu/covid-19/entity/32439716_HAS_TOPIC_C1458155> <https://research.tib.eu/covid-19/entity/32439716_HAS_TOPIC_C1515090> <https://research.tib.eu/covid-19/entity/32439716_HAS_TOPIC_C1615608> <https://research.tib.eu/covid-19/entity/32439716_HAS_TOPIC_C2718080> <https://research.tib.eu/covid-19/entity/32439716_HAS_TOPIC_C3694279> <https://research.tib.eu/covid-19/entity/32439716_HAS_TOPIC_C4704874> <https://research.tib.eu/covid-19/entity/32439716_HAS_TOPIC_C5203670> <https://research.tib.eu/covid-19/entity/32439716_HAS_TOPIC_C5203676> <https://research.tib.eu/covid-19/entity/32439716_HAS_TOPIC_C5392141>
?:authorAffiliation	[\'Institut Jules Bordet and l\'Université Libre de Bruxelles (U.LB), Brussels, Belgium.\', \'European Institute of Oncology (IEO) IRCCS, Milan, Italy.\', \'GBG Forschungs GmbH, Neu-Isenburg, Germany.\', \'Oncology, Gustave Roussy and Paris-Saclay University, Villejuif, Île-de-France, France.\', \'Department of Oncology and Radiotherapy, Medical University of Gdańsk, Gdańsk, Poland.\', \'European Institute of Oncology IRCCS, Milan, Italy.\', \'Iridium Kankernetwerk and University of Antwerp, Antwerp, Belgium.\', \'Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria.\', \'Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy.\', \'IOB, Institute of Oncology, Quiron Group (Madrid & Barcelona); Vall d\'Hebron institute of Oncology (VHIO) (Barcelona), Barcelona, Madrid, Spain.\', \'Breast Unit, Champalimaud Clinical Center/Champalimaud Foundation, Lisbon, Portugal.\', \'Division of Oncology, Shaare Zedek Medical Centre, Jerusalem, Jerusalem, Israel.\', \'Department of Oncology and Hemato-Oncology, University of Milano and European Institute of Oncology, IRCCS, Milano, Italy giuseppe.curigliano@ieo.it.\']
?:citedBy	-1
?:creator	<https://research.tib.eu/covid-19/entity/Cardoso_Fatima> <https://research.tib.eu/covid-19/entity/Cortes_Javier> <https://research.tib.eu/covid-19/entity/Criscitiello_Carmen> <https://research.tib.eu/covid-19/entity/Curigliano_Giuseppe> <https://research.tib.eu/covid-19/entity/Delaloge_Suzette> <https://research.tib.eu/covid-19/entity/Di_Cosimo_Serena> <https://research.tib.eu/covid-19/entity/Gnant_Michael> <https://research.tib.eu/covid-19/entity/Loibl_Sibylle> <https://research.tib.eu/covid-19/entity/Paluch-Shimon_Shani> <https://research.tib.eu/covid-19/entity/Poortman_Philip> <https://research.tib.eu/covid-19/entity/Senkus_Elzbieta> <https://research.tib.eu/covid-19/entity/Trapani_Dario> <https://research.tib.eu/covid-19/entity/de_Azambuja_Evandro>
?:doi	<https://research.tib.eu/covid-19/entity/e00079310.1136/esmoopen-2020-000793>
?:doi	e00079310.1136/esmoopen-2020-000793
?:hasPublicationType	<https://research.tib.eu/covid-19/entity/Journal_Article> <https://research.tib.eu/covid-19/entity/Practice_Guideline> <https://research.tib.eu/covid-19/entity/Review>
?:journal	ESMO open
is ?:pmid of	<https://research.tib.eu/covid-19/entity/32439716>
?:pmid	<https://research.tib.eu/covid-19/entity/32439716>
?:pmid	32439716
?:publication_isRelatedTo_Disease	<https://research.tib.eu/covid-19/entity/Covid-19>
?:rankingScore_SJR	-1.0
?:rankingScore_hIndex	-1
is ?:relation_isRelatedTo_publication of	<https://research.tib.eu/covid-19/entity/C2948600_TREATS_C0006142>
?:title	ESMO Management and treatment adapted recommendations in the COVID-19 era: Breast Cancer.
?:type	<https://research.tib.eu/covid-19/vocab/Publication> <https://research.tib.eu/covid-19/vocab/Publication_Author>
?:year	2020

Property

Value

is ?:annotates of

?:authorAffiliation

[\'Institut Jules Bordet and l\'Université Libre de Bruxelles (U.LB), Brussels, Belgium.\', \'European Institute of Oncology (IEO) IRCCS, Milan, Italy.\', \'GBG Forschungs GmbH, Neu-Isenburg, Germany.\', \'Oncology, Gustave Roussy and Paris-Saclay University, Villejuif, Île-de-France, France.\', \'Department of Oncology and Radiotherapy, Medical University of Gdańsk, Gdańsk, Poland.\', \'European Institute of Oncology IRCCS, Milan, Italy.\', \'Iridium Kankernetwerk and University of Antwerp, Antwerp, Belgium.\', \'Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria.\', \'Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy.\', \'IOB, Institute of Oncology, Quiron Group (Madrid & Barcelona); Vall d\'Hebron institute of Oncology (VHIO) (Barcelona), Barcelona, Madrid, Spain.\', \'Breast Unit, Champalimaud Clinical Center/Champalimaud Foundation, Lisbon, Portugal.\', \'Division of Oncology, Shaare Zedek Medical Centre, Jerusalem, Jerusalem, Israel.\', \'Department of Oncology and Hemato-Oncology, University of Milano and European Institute of Oncology, IRCCS, Milano, Italy giuseppe.curigliano@ieo.it.\']

?:citedBy